Amphotericin B and its lipid formulations;Amphotericin B und seine Lipidcarrier

Krankenhauspharmazie

Volumn 18, Issue 3, 1997, Pages 104-113

  Lipp, Hans Peter ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AmBisome; amphotericin B; intralipid; lipid formulations

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CHOLESTEROL SULFATE; INTRALIPID; LIPID EMULSION;

DRUG FORMULATION; DRUG MONITORING; HUMAN; MYCOSIS; NEPHROTOXICITY; REVIEW;

EID: 0030938363     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(Suppl 5):S3-S7.
2. Amantea MA, Bowden RA, Forrest A, et al. Population pharmacokinetics and renal function-sparing effects of Aamphotericin B colloidal dispersion in patients receiving bone marrow transplantation. Antimicrob Agents Chemother 1995;39:2042-7.
3. Anderson RP, Clark DA Amphotericin B toxicity reduced by administration in fat emulsion Ann Pharmacother 1995:29; 496-500.
4. Aming M, Heer-Sonderhoff AH, Wehmeier A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995; 14(1):41-3.
5. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995,38:459-65.
6. Aming M, Scharf RE Prevention of amphotericinB-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989,67:1020-8.
7. Ayestaran A, Lopez RM, Montoro JB, et al. Pharmacokinetics of conventional formulation versus fat emulsion formulations of amphotericia B in a group of patients with neutropenia Antimicrob Agents Chemother 1996;40:609-12.
8. Barwicz J, Christian S, Gruda I. Effects of the Aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 1992;36:2310-5.
9. Behre GF, Schwartz S, Lenz K, et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic patients. Ann Hematol 1995;71:287-91.
10. Beyer J, Schwartz S, Heinemann V, Siegert W. Strategies in prevention of invasive aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother 1994;38:911-7.
11. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral penoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Transplantation 1991;51.925-7
12. Blumberg EA, Reboli AC Failure of systemic em-pirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 1996;22:462-6
13. Blume G, Cevc G, Crommelin MDJA, et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulating times. Biochim Biophys Acta 1993;1149.180-4.
14. Bow EJ, Loewen R, Cheang MS, Schacter B, Invasive fungal diseases in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen Clin Infect Dis 1995;21:361-9.
15. Bowden RA, Cays M, Gooley T, et al Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
16. Brajtburg J, Powderly WG, Kobayashi GS, Medoff G Amphotericin B: delivery systems. Antimicrob Agents Chemother 1990;34:381-4
17. Branch RA Prevention of amphotericin-B-induced renal impairment - a review on the use of sodium supplement Arch InternMed 1988,148:2389-94.
18. British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of anic;ifungal chemotherapy. Lancet 1991;337;1577-80
19. Caillot D, Casanovas O, Solary E, et al. Efficacy and safety of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31: 161-9.
20. Caillot D, Reny G, Solary E, et al A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with haemotological malignancies J Antimicrob Chemother 1994;3.603-13.
21. Chavanet P, Caillot D. Lipid-based formulations of amphotericin B (Reply). J Antimicrob Chemother 1995;35.711-3
22. Chia JK, McManus EJ In vitro TNF induction assay for analysis of febrile toxicity association with amphotericin B preparations Antimicrob Agents Chemother 1990,4.906-8.
23. Chopra R, Blair S, Strang J, et al Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991,28(Suppl.B):93-104.
24. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 1996;30.409-12.
25. Collette N, van der Auwera P, Meunier F, et al. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991;27:535-48
26. Coleman JM, Hogg GG, Rosenfeld JV, Waters KD Invasive central nervous system aspergillosis: cure with liposomal amphotericin B, itraconazole, and radical surgery - case report and review of the literature. Neurosurgery 1995;36:858-63.
27. Davis SS, Washington C, West P, Illum G, et al. Lipid emulsions as drug delivery systems. Ann NY Acad Sci 1988; 507.75-88
28. de Marie S, Janknegt R, Bakker-Woudenberg IAJM Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-16.
29. Dornbusch HJ, Urban CE, Pinter H, et al. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using AmBisome, G- CSF and surgery. Report of five cases. Pediat Hematol Oncol 1995;12:577-86.
30. Emminger W, Graninger W, Emminger-Schmidmeier W, et al. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol 1994;68:27-31.
31. Ericsson O, Hallmen A-C, Wirkstrom I. Amphotericin B is incompatible with lipid emulsion. Ann Pharmacother 1996;30:298
32. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics and antifungal therapy Clin Infect Dis 1992;15:1003-18.
33. Fromtling RA Amphotencin B cholesterol sulfate complex (colloidal dispersion). Drugs Future 1993;18:303-6.
34. Fromtling RA, Castaner J. Voriconazole. Drugs Future 1996;21(3):266-71.
35. Gales MA, Gales BJ, Rapid infusions of amphotencin B in dextrose. Ann Pharmacother 1995;29.523-9
36. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12.308-29
37. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever production by infusing amphotericin B J Infect Dis 1987;156.784-9
38. Goldstone AH, O'Driscoll A. Early AmBisome in febrile neutropenia in patients with haematological disorders. Bone Marrow Transplant 1994;14 (Suppl 5):S15-S17.
39. Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
40. Graybill JR Lipid formulations for amphotericin B: does the emperor need new clothes? Ann Intern Med 1996;124:921-3.
41. Graybill JR Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 1994;28(Suppl I):17-24
42. Gutierrez F, Wall PG, Cohen J. An audit of the use of antifungal agents. J Antimicrob Chemother 1996; 37.175-85
43. Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion Antimicrob Agents Chemother 1992,36 486-8.
44. Hay RJ. Liposomal amphotericin B, AmBisome. J Infect 1994;28:Suppl I,35-43
45. Heidemann HT, Gerkens JF, Spickard WA, Lackson EK, et al. Amphotencin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983.75.476 81
46. Heinemann V, Kähny B, Devbus A, Wachholz K, et al. Pharmacokinetics of liposomal amphotencin B (AmBisome) versus other lipid-based formulations. Bone Marrow Transplant 1994;14(Suppl.5): S8-S9.
47. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmaeokinet 1992;23:279-91.
48. Janoff AS, Boni LT, Popescu MC. et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci 1988,85.6122-6.
49. Joly V, Farinotti R, St -Julien L, et al. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (fungizone) associated with intralipid. Antimicrob Agents Chemother 1994;38:177-83.
50. Joly V, Geoffray C, Reynes J, Goujard C. et al Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J Antimicrob Chemother 1996;38:117-26.
51. Kan VL, Bennett JE, Amantea MA, et al Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers J Infect Dis 1991;164:418-21.
52. Khoo SH, Bond J, Denning DW. Administering amphotericin B - a practical approach. J Antimicrob Chemother 1994;34:203-13.
53. Kintzel PE, Smith GH. Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pharm 1992;49:1156-64.
54. Kirsh R, Goldstem R, Tarloff J, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis J Infect Dis 1988;158:1065-70.
55. Kline S, Larsen TA, Fieber L, et al Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin Infect Dis 1995;21:1154-8.
56. Lance MR, Washington C, Davis SS. Structure and toxicity of amphotencin B/triglyceride emulsion formulations. J Antimicrob Chemother 1995,36:119-28.
57. Leake HA, Appleyard MN, Hartley JPR. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect 1994;28:319-22
58. Legrand P, Vertut-Doi A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother 1996;37-519-53.
59. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991;114:664-6.
60. Lipp H-P, Schuler U, Saal J, Schaaf D. Amphotericin B in Fettemulsionen - Vorteile gegenüber der konventionellen Therapie Arzneimitteltherapie 1993;11:319-26.
61. Lipp H-P. Klinische Pharmakokinetik von Itraconazol. Krankenhauspharmazie 1996;17:388-95.
62. Longuet P, Joly V, Amirault P, Seta N, et al. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotencin B infusions in rats. Antimicrob Agents Chemother 1991;35:1303-8.
63. Louie A, Baltch AL, Franke MA, et al. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce TNF alpha, an effect that is attenuated by pentoxifylline, liposomal vesicles and dexamethasone. J Antimicrob Chemother 1994;34:975-87
64. Lupinetti FM, Behrendt DM, Giller RH, et al. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992;104:684-7.
65. Macedo MCMA, Dulley FL, Ostronoff M. Machedo CM, et al. Effectiveness of amphotencin B in lipid emulsion for treating fungal septicemia in granulocytopenic patients. Clin Infect Dis 1994;19:367-8.
66. Meunier F Alternative modalities of administering amphotencin B. current issues. J Infect 1994;28 (Suppl I) 51-6.
67. Mills W, Chopra R, Linch DC, et al. Liposomal amphotencin B in the treatment of fungal infections in neutropenic patients. a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994: 86.754-60.
68. Moreau P. Lipid-based formulations of amphotericin B - reply. J Antimicrob Chemother 1995;35:711-3.
69. Müller J Die Epidemiologie tieflokalisierter Mykosen Mycoses 1994;37(Suppl 2):1-7.
70. Nagata MP, Gentry CA, Hampton EM. Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? Ann Pharmacother 1996;30:811-8.
71. Nicholl TA, Nimmo CR, Shepherd JD. et al. Amphotencin B infusion-related toxicity. comparison of two- and four-hour infusions. Ann Pharmacother 1995;29:1081-7.
72. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses, Clin Infect Dis 1995;21:1145-53.
73. Oravcova E, Mistrik M, Drgona L, et al. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. Chemotherapy 1995;41:473-6.
74. Pahls S, Schaffner A Comparison of the activity of free and liposomal amphotericin B in vitro and in a mode! of systemic and localized murine candidiasis. J Infect Dis 1994;169.1057-61.
75. Pascual B, Ayestaran A, Montoro JB, et al. Administration of lipid-emulsion versus conventional amphoiericin B in patients with neutropenia. Ann Pharmacother 1995;29:1197-201.
76. Petit N, Parola P, Dhiver C, Gastaut J-A. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients J Antimicrob Chemother 1996; 33:154-7.
77. Presterl E, Laßnigg A, Willinger B, Graninger W. Candida-Infektionen in der Intensivmedizin. Anaesthesist 1996;45:195-210.
78. Ranchère JY, Latour JF, Fuhrmann C, et al. Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother 1996; 37.1165-9.
79. Reeves DS, MacGowan AP, Holt HA, Lovering AM, et al. Therapeutic monitoring of antimicrobials, a summary of the information presented at the UK NEQAS for antibiotic assays meeting the participants, October 1993. J Antimicrob Chemother 1995;35:213-26.
80. Ringden O, Andstrom E, Remberger M, Svahn BM, et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin Bone Marrow Transplant 1994,14 (Suppl 5):S10-S14.
81. Ringden O, Meunier F, Tollemar J, Ricci P, et al. Efficacy of amphotencin B encapsulated in liposomes (AmBisome) in the treatment of inva-sive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 (Suppl B): 73-82
82. Ringden O, Tollemar S. Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections m immunocompromised children Mycoses 1993; 36 187-92
83. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B prophylaxis against invasive aspergillus infections in allogenic marrow transplantation. Am J Med 1991;91:484-92.
84. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity. the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64
85. Schmitt H-J. New methods of delivery of amphotericin B clinical infectious diseases 1993;17 (Suppl 2):S501-6.
86. Schneemann H. Liposomales Amphotericin B. Krankenhauspharmazie 1992;13:161-71
87. Schricker Th, Georgieff M. Fett in der parenteralen Emährungstherapie. Anästhesiol Intensivmed Notfallmed Schmerzther 1994;29:137-45.
88. Schuler U. Amphotencin B - neue Darreichungsforraen eines bewährten Antimykotikums - eine Stellungnahme. Arzneimitteltherapie 1994;12:118-9.
89. Sivakumaran M, Swann RA, Mitchell VE, et al Therapeutic efficacy of AmBisome: a cautionary note. Am J Hematol 1995,48(3):208-9.
90. Smith TM, Strzyk WR. Lack of nephrotoxicity with administration of amphotericin B in a hpid emulsion. Ann Pharmacother 1994;28.1307.
91. Stevens DA Overview of amphotericin B colloidal dispersion (Amphocil). J Infect 1994;28 Suppl I;45-9.
92. Sugar AM. Use of Amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995,39:1907-12.
93. Tebbs SE, Veale EL, Elliott TSJ. A comparison of the in-vitro activity of amphotericin B with that of liposomal amphotericin B against Candida albicans colonising central venous catheters. J Antimicrob Chemother 1994,34:840-1.
94. Tollemar J, Ringden O. for the AmBisome users group. Early pharmacokinetic and clinical results from a noncomparative multicentre trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome). Drug Invest 1992;4(3):232-8.
95. Tollemar J, Ringden O, Anderssom S, et al. Prophylacuc use of AmBisome against fungal infections. A randomized trial in bone marrow transplant recipients Transplant Proc 1993;25: 1495-7.
96. Tommee JFC, Mannes GPM, van der Bij W, et al. Serodiagnosis and monitoring of aspergillus infections after lung transplantation. Ann Intern Med 1996;125:197-201.
97. Trigg ME, Menezes AH, Giller R, et al. Combined antifungal therapy and surgical resection as treatment of disseminated aspergillosis of the lung and brain following BMT. Bone Marrow Transplant 1993;11:492-6.
98. Trissel LA, Slimowitz R, Castor P, et al. Amphotericin B does not mix with fat emulsion. Am J Health-Syst Pharm 1995;52:1463-4
99. van Etten EWM, Chander HR, Snijders SV, Bakker-Woudenberg IAJM Interaction of liposomal amphotericin B with extracellular and intracellular Candida albicans. J Antimicrob Chemother 1995; 36:961-74.
100. Vita E, Schroeder DJ. Intralipid in prophylaxis of amphotencin B nephrotoxidty. Ann Pharmacother 1994;28:1182-3.
101. Viviani MA, Rizzardini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994;22:137-42.
102. Walev I, Bhakdi S. Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob Agents Chemother 1996;40:1116-20.
103. Walsh TJ, Lee JW. Prevention of invasive fungal infections in patients with neoplastic diseases. Clin Infect Dis 1993;17(Suppl. 2):468-S480.
104. Warnock DW. Fungal complications of transplantation: diagnosis, treatment and prevention. J Antimicrob Chemother 1995;36(Suppl B):73-90.
105. Wasan KM, Conklin JS. Evaluation of renal toxicity and antifungal activity of free and liposomal amphotencin B following a single intravenous dose to diabetic rats with systemic candidiasis. Antimicrob Agents Chemother 1996;40:1806-10.
106. Washington C, Davis SS An emulsion formulation of amphotericin B. UK Patent application 8714652; 1987.
107. Washington C, Taylor SJ, Davis SS. The structure of colloidal formulations of amphotencin B Int J Pharm 1988,46:25-30.
108. Hiemenz JW, Walsh TJ Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(Suppl 2):133-44.
109. Sievers TM, Kubak BM. Wong-Beringer A. Safety and efficacy of intralipid emulsions of amphotericin B. J Antimicrob Chemother 1996;38:333-47.